LAURIE J. OLSON - 03 Apr 2023 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role
Director
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Apr 2023
Net transactions value
-$96,160
Form type
4
Filing time
05 Apr 2023, 16:55:24 UTC
Previous filing
04 Jan 2023
Next filing
22 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $84,860 +1,000 $84.86 1,000 03 Apr 2023 Direct F1
transaction KRTX Common Stock Sale $181,020 -1,000 -100% $181.02 0 03 Apr 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -1,000 -6.7% $0.000000 14,000 03 Apr 2023 Common Stock 1,000 $84.86 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2022.
F2 This option vests and becomes exercisable in thirty-six equal monthly installments beginning on August 12, 2020.